SPRY · ARS Pharmaceuticals, Inc.
$4.76
-5.93% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-5.6
Dividend yield
—
Beta
1.00
Avg volume
2M
Employees
0K
Daily Change %
-5.93%
5 Days Change
-6.94%
10 Days Change
-12.83%
30 Days Change
-12.10%
60 Days Change
-34.13%
Month to Day Change
-9.36%
Year to Day Change
-55.11%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SPRY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-13
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Leerink Partners | Maintains | Outperform | $24.00 → $18.00 |
| 2026-06-25 | Leerink Partners | Maintains | Outperform | $25.00 → $24.00 |
| 2026-05-28 | Cantor Fitzgerald | Maintains | Overweight | $12.00 → $30.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 31 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 23.5% below the 50-day MA ($6.22).
- Price vs 200-day MA: Trading 44.1% below the 200-day MA ($8.52).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.06) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($4.76).
SPRY Price Chart
Loading chart for SPRY…
Fundamentals
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.